Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

20002,184 citationsJournal Article

Authors

Frances A. Shepherd · Regional Cancer Center

Janet Dancey · Regional Cancer Center

Rodryg Ramlau · Regional Cancer Center

K. Mattson · Regional Cancer Center

Richard J. Gralla · Regional Cancer Center

Mark Allen O’Rourke · Regional Cancer Center

Nathan Levitan ·

Abstract

Treatment with docetaxel is associated with significant prolongation of survival, and at a dose of 75 mg/m(2), the benefits of docetaxel therapy outweigh the risks.

Topics & Keywords

Lung Cancer Diagnosis and Treatment Lung Cancer Treatments and Mutations Lung Cancer Research Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 18, Issue 10, pp. 2095-2103

DOI: 10.1200/jco.2000.18.10.2095

Field-Weighted Citation Impact: 83.45